The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  European Journal of Pharmacology

• Publication date

  2001-06-29

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/S0014-2999(01)01087-1PMID 11438309
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mapping of serotonin 5‐HT4 receptor mRNA and ligand binding sites in the post‐mortem human brain

  2000cited by this paper
• 5‐HT4 receptors on cholinergic nerves involved in contractility of canine and human large intestine longitudinal muscle

  2000cited by this paper
• An improved in vitro bioassay for the study of 5‐HT4 receptors in the human isolated large intestinal circular muscle

  2000cited by this paper
• Integrated modelling of the clinical pharmacokinetics of SDZ HTF 919, a novel selective 5-HT4 receptor agonist, following oral and intravenous administration.

  1999cited by this paper
• Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans

  1999cited by this paper
• Pharmacological characterization of 5‐HT4 receptors mediating relaxation of canine isolated rectum circular smooth muscle

  1999cited by this paper
• Effect of a novel prokinetic drug, R093877, on gastrointestinal transit in healthy volunteers

  1998cited by this paper
• Agonistic properties of alniditan, sumatriptan and dihydroergotamine on human 5‐HT1B and 5‐HT1D receptors expressed in various mammalian cell lines

  1998cited by this paper
• Concentration-dependent stimulation of cholinergic motor nerves or smooth muscle by [Nle13]motilin in the isolated rabbit gastric antrum.

  1997cited by this paper
• SOME QUANTITATIVE USES OF DRUG ANTAGONISTS

  1997cited by this paper
• Motilin and clinical application.

  1997cited by this paper
• Characterization of the contraction to 5‐HT in the canine colon longitudinal muscle

  1997cited by this paper
• Muscarinic receptor subtypes and smooth muscle function.

  1996cited by this paper
• SPECIAL REPORT Stimulation of cyclic AMP formation in the circular smooth muscle of human colon by activation of 5‐HT4‐like receptors

  1996cited by this paper
• Functional evidence for a 5‐HT2B receptor mediating contraction of longitudinal muscle in human small intestine

  1995cited by this paper
• Gastrointestinal prokinetic benzamides: the pharmacology underlying stimulation of motility.

  1995cited by this paper
• Coexpression of 5-HT2A and 5-HT4 receptors coupled to distinct signaling pathways in human intestinal muscle cells.

  1995cited by this paper
• Nonlinear regression using spreadsheets.

  1995cited by this paper
• An enhancing effect of 5‐hydroxytryptamine on electrically evoked atropine‐resistant contraction of guinea‐pig proximal colon

  1995cited by this paper
• Cholecystokinin receptors.

  1995cited by this paper
• Characterization of the 5‐hydroxytryptamine receptor type involved in inhibition of spontaneous activity of human isolated colonic circular muscle

  1994cited by this paper
• Cloning and functional characterization of the human 5‐HT2B serotonin receptor

  1994cited by this paper
• GR113808: a novel, selective antagonist with high affinity at the 5‐HT4 receptor

  1994cited by this paper
• Further characterization of 5‐hydroxytryptamine receptors (putative 5‐HT2B) in rat stomach fundus longitudinal muscle

  1994cited by this paper
• Pharmacological characterization of 5‐hydroxytryptamine receptor types in the guinea‐pig proximal colon

  1993cited by this paper
• Prokinetic agents for lower gastrointestinal motility disorders

  1993cited by this paper
• Effects of 5-HT4 receptor stimulation on basal and electrically evoked release of acetylcholine from guinea-pig myenteric plexus

  1992cited by this paper
• Combined dose‐ratio analysis of cholecystokinin receptor antagonists, devazepide, lorglumide and loxiglumide in the guinea‐pig gall bladder

  1992cited by this paper
• 5-Hydroxytryptamine4 receptors mediate relaxation of the rat oesophageal tunica muscularis mucosae

  1991cited by this paper
• Selective and functional 5-hydroxytryptamine3 receptor antagonism by BRL 43694 (granisetron).

  1989cited by this paper
• Treatment of chronic constipation with cisapride and placebo.

  1987cited by this paper
• Giant migrating contractions during defecation in the dog colon.

  1987cited by this paper
• A microcomputer program for fitting enzyme inhibition rate equations.

  1987cited by this paper
• Identification of 5HT2-receptors on longitudinal muscle of the guinea pig ileum.

  1984cited by this paper
• Vascular effects of ketanserin (R 41 468), a novel antagonist of 5-HT2 serotonergic receptors.

  1981cited by this paper
• Motor activity of the sigmoid colon in chronic constipation: comparative study with normal subjects.

  1979cited by this paper
• Distribution of acetylcholinesterase and butyrylcholinesterase in the myenteric plexus and longitudinal muscle of the guinea-pig intestine.

  1971cited by this paper

• 5-Hydroxytryptamine receptors in GtoPdb v.2025.3

  2025cites this paper
• Current Treatment Options for Children with Functional Constipation—What Is in the Pipeline?

  2025cites this paper
• 5-Hydroxytryptamine receptors in GtoPdb v.2025.1

  2025cites this paper
• A Compressive Review on Advances in Analytical Methodologies for Prucalopride

  2025cites this paper
• The impact of long‐course chemoradiotherapy on the myenteric plexus, neuromuscular functions and responses to prokinetic drugs in the human rectum

  2024cites this paper
• Evaluation and management of pediatric refractory constipation: Recommendations from the NASPGHAN neurogastroenterology and motility committee.

  2024cites this paper
• A non-invasive tool to collect small intestine content in post weaning pigs: validation study

  2024cites this paper
• Serotoninergic Mechanisms of Action in the Relaxant Properties of Saccharomyces boulardii CNCM I-745 on the Intestine

  2024cites this paper
• Sampling intestinal microbiota in growing pigs: evaluation of CapSa, an ingestible capsule

  2024cites this paper
• Eco-friendly-assessed micellar-fluorimetric platform for concurrent analysis of empagliflozin and prucalopride succinate in biological fluids: Docking simulation.

  2023cites this paper
• Review article: An analysis of the pharmacological rationale for selecting drugs to inhibit vomiting or increase gastric emptying during treatment of gastroparesis

  2023cites this paper
• Clinical utility of colon capsule endoscopy: a moving target?

  2023cites this paper
• 5-Hydroxytryptamine receptors in GtoPdb v.2023.1

  2023cites this paper
• A Review of the Cardiovascular Safety of Prucalopride in Patients With Chronic Idiopathic Constipation

  2023cites this paper
• Serotonin G Protein-Coupled Receptor-Based Biosensing Modalities in Yeast

  2022cites this paper
• Gastrointestinal Dysfunction in Parkinson’s Disease

  2022cites this paper
• Preclinical experimental models for assessing laxative activities of substances/products under investigation: a scoping review of the literature.

  2022cites this paper
• Hormonal profile and haematological parameters of Wistar albino rats treated with methanolic and aqueous leaf extracts of Schleichera oleosa

  2021cites this paper
• Female predominance in gastroparesis

  2021cites this paper
• Serotonin GPCR-based biosensing modalities in yeast

  2021cites this paper
• A Validated Stability-Indicating Method for Separation of Prucalopride Drug by HPLC: Method Transfer to UPLC

  2021cites this paper
• Management of Ineffective Esophageal Hypomotility

  2021cites this paper
• Role of Prucalopride in Treating Functional Constipation and Gastroparesis: A Systemic Review

  2021cites this paper
• Prucalopride in diabetic and connective tissue disease‐related gastroparesis: Randomized placebo‐controlled crossover pilot trial

  2020cites this paper
• Genotoxicity and carcinogenicity risk assessment of prucalopride, a selective 5-hydroxytryptamine 4 receptor agonist.

  2020cites this paper
• Pharmacology of Serotonin and Its Receptors

  2020cites this paper
• High‐resolution manometry reveals different effect of polyethylene glycol, bisacodyl, and prucalopride on colonic motility in healthy subjects: An acute, open label, randomized, crossover, reader‐blinded study with potential clinical implications

  2020cites this paper
• Haematology, serum biochemistry and histopathological findings associated with sub-chronic administration of methanol leaf extract of Pterocarpus santalinoides DC in albino rats

  2020cites this paper
• Effect of prucalopride on sildenafil‐induced inhibition of esophageal peristalsis in healthy adults

  2020cites this paper
• Efficacy and Tolerability of Prucalopride in Bowel Preparation for Colonoscopy: A Systematic Review and Meta-Analysis

  2020cites this paper
• Gastroparesis and Cancer-Related Gastroparesis

  2019cites this paper
• Does prucalopride reduce the dose of sodium phosphate in bowel preparation? A single‐blind, randomized, and prospective study

  2019cites this paper
• 5-Hydroxytryptamine receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database

  2019cites this paper
• An overview of the efficacy and safety of prucalopride for the treatment of chronic idiopathic constipation

  2019cites this paper
• Luminal 5‐HT4 receptors—A successful target for prokinetic actions

  2019cites this paper
• Use of prucalopride in adults with chronic idiopathic constipation

  2019cites this paper
• Nonclinical Cardiovascular Studies of Prucalopride, a Highly Selective 5-Hydroxytryptamine 4 Receptor Agonist

  2018cites this paper
• Influence of prucalopride on esophageal secondary peristalsis in reflux patients with ineffective motility

  2018cites this paper
• Cardiovascular effects of cisapride and prucalopride on human 5-HT4 receptors in transgenic mice

  2018cites this paper
• The extracellular matrix glycoprotein tenascin‐X regulates peripheral sensory and motor neurones

  2018cites this paper
• The 5-HT4 Receptor Agonist Prucalopride Stimulates Mucosal Growth and Enhances Carbohydrate Absorption in the Ileum of the Mouse

  2018cites this paper
• Efficacy and safety of prucalopride in the treatment of chronic constipation

  2018cites this paper
• 4-Substituted and 1,4-Disubstituted Piperidines

  2018cites this paper
• Preoperative administration of the 5-HT4 receptor agonist prucalopride reduces intestinal inflammation and shortens postoperative ileus via cholinergic enteric neurons

  2018cites this paper
• Metoclopramide

  2017cites this paper
• Serotonin 4 Receptors: A Cornerstone in Anorexia Nervosa?

  2017cites this paper
• Can prucalopride improve the efficacy and tolerability of colonoscopy preparation ?

  2017cites this paper
• The biasing of the 5-HT4 receptor as an antidepressant target

  2017cites this paper
• The Effect of Prucalopride on Small Bowel Transit Time in Hospitalized Patients Undergoing Capsule Endoscopy

  2017cites this paper
• Prucalopride and Varenicline (Champix): Case Report of a Possible Drug Interaction at Enteric Serotonin (5-Ht) Receptors

  2017cites this paper
• The 5-HT4 receptor agonist prucalopride does not facilitate cholinergic neurotransmission in circular and longitudinal smooth muscle preparations of equine mid-jejunum.

  2017cites this paper
• Preliminary safety and efficacy profile of prucalopride in the treatment of systemic sclerosis (SSc)-related intestinal involvement: results from the open label cross-over PROGASS study

  2017cites this paper
• YH12852, a potent and highly selective 5‐HT4 receptor agonist, significantly improves both upper and lower gastrointestinal motility in a guinea pig model of postoperative ileus

  2017cites this paper
• An update on prucalopride in the treatment of chronic constipation

  2017cites this paper
• Gastrointestinal dysmotility disorders in critically ill dogs and cats.

  2016cites this paper
• Definition, diagnosis and treatment strategies for opioid-induced bowel dysfunction–Recommendations of the Nordic Working Group

  2016cites this paper
• Patient considerations in the management of chronic constipation: focus on prucalopride

  2016cites this paper
• [Current Status of Translational Research on Constipation].

  2016cites this paper
• Patient considerations in the management of chronic constipation: focus on prucalopride

  2016cites this paper
• efinition , diagnosis and treatment strategies for opioid-induced owel dysfunction — Recommendations of the Nordic Working Group sbjørn

  2016cites this paper
• Tracking gastrointestinal transit of solids in aged rats as pharmacological models of chronic dysmotility

  2016cites this paper
• Serotonin transporter variant drives preventable gastrointestinal abnormalities in development and function.

  2016influential citation
• Effects of prucalopride on esophageal secondary peristalsis in humans

  2016cites this paper
• Activation of islet 5-HT4 receptor regulates glycemic control through promoting insulin secretion.

  2016cites this paper
• Pharmacokinetics and tissue distribution study of prucalopride in rats by ultra high performance liquid chromatography with tandem mass spectrometry.

  2016cites this paper
• Research progress on drugs in treatment of chronic constipation

  2016cites this paper
• Efficacy and safety of prucalopride in adults and children with chronic constipation

  2015cites this paper
• Reflux, belching, rumination and their interrelationships

  2015cites this paper
• Prucalopride: A Review in Chronic Idiopathic Constipation

  2015cites this paper
• Prucalopride decreases esophageal acid exposure and accelerates gastric emptying in healthy subjects

  2014cites this paper
• 5-HT4 Receptor Agonists in the Treatment of Gastrointestinal Motility Disorders: Current Status and Perspective

  2014cites this paper
• Regionally dependent neuromuscular functions of motilin and 5‐HT4 receptors in human isolated esophageal body and gastric fundus

  2014cites this paper
• Efficacy and safety of prucalopride in children with functional constipation: A randomized, multicenter, placebo-controlled trial

  2014cites this paper
• New pharmacological treatment options for chronic constipation

  2014cites this paper
• UvA-DARE ( Digital Academic Repository ) Unraveling childhood constipation : Pathophysiology , diagnostics and treatment

  2014cites this paper
• Drugs acting at 5‐HT4, D2, motilin, and ghrelin receptors differ markedly in how they affect neuromuscular functions in human isolated stomach

  2014cites this paper
• Prucalopride is no more effective than placebo for children with functional constipation.

  2014cites this paper
• Prucalopride Improves Bowel Function and Colonic Transit Time in Patients With Chronic Constipation: An Integrated Analysis

  2014cites this paper
• Histopathologic findings in patients with idiopathic megacolon: a comparison between dilated and non‐dilated loops

  2014cites this paper
• SSP-002392, a new 5-HT4 receptor agonist, dose-dependently reverses scopolamine-induced learning and memory impairments in C57Bl/6 mice.

  2014cites this paper
• Radiosynthesis and preclinical evaluation of [11C]prucalopride as a potential agonist PET ligand for the 5-HT4 receptor

  2013cites this paper
• The Effects of Prucalopride on Postoperative Ileus in Guinea Pigs

  2013cites this paper
• Efficacy and safety of oral prucalopride in women with chronic constipation in whom laxatives have failed: an integrated analysis

  2013cites this paper
• Novel Pharmacological Therapies for Management of Chronic Constipation

  2013cites this paper
• Newer agents for constipation: prucalopride

  2013cites this paper
• 5-HT Actions in the Human Submucous Plexus

  2013cites this paper
• Pharmacokinetic and pharmacodynamic considerations for the current chronic constipation treatments

  2013cites this paper
• Prucalopride: A Review of Its Use in the Management of Chronic Constipation

  2013cites this paper
• Discovery, oral pharmacokinetics and in vivo efficacy of a highly selective 5-HT4 receptor agonist: clinical compound TD-2749.

  2012cites this paper
• Discovery, oral pharmacokinetics and in vivo efficacy of velusetrag, a highly selective 5-HT(4) receptor agonist that has achieved proof-of-concept in patients with chronic idiopathic constipation.

  2012cites this paper
• Systematic review: cardiovascular safety profile of 5-HT4 agonists developed for gastrointestinal disorders

  2012cites this paper
• Synthetic approaches to the 2010 new drugs.

  2012cites this paper
• Prucalopride

  2012influential citation
• The 5-Hydroxytryptamine4 Receptor Agonists Prucalopride and PRX-03140 Increase Acetylcholine and Histamine Levels in the Rat Prefrontal Cortex and the Power of Stimulated Hippocampal θ Oscillations

  2012cites this paper
• The enteric serotonergic system is altered in patients with diverticular disease

  2012cites this paper
• Prucalopride: evaluation of the pharmacokinetics, pharmacodynamics, efficacy and safety in the treatment of chronic constipation

  2012influential citation
• Clinical and economic profile of prucalopride in the treatment of chronic constipation in women

  2012cites this paper
• The Pharmacology of TD-8954, a Potent and Selective 5-HT4 Receptor Agonist with Gastrointestinal Prokinetic Properties

  2011influential citation
• Randomised clinical trial: the efficacy of prucalopride in patients with chronic intestinal pseudo-obstruction - a double-blind, placebo-controlled, cross-over, multiple n = 1 study

  2011cites this paper
• Neue Arzneimittel für Kleintiere 2010

  2011cites this paper